Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

AntriaBio Looks To Corner The Long-Acting Insulin Market

We believe investors should 'Buy' AntriaBio, Inc. (OTCQB:ANTB) (post-split (OTCQB:ANTBD)), and our target is $5.25 per share. AntriaBio's lead product, AB101, is an ultra-long acting recombinant human insulin with a planned once-a-week dosing schedule that is intended for use in patients with both type 1 and type 2 diabetes. The compound is administered by subcutaneous injection and specifically formulated to release insulin slowly and uniformly over a sustained period of approximately one week without an adverse initial burst of insulin.

We believe that AB101 has tremendous potential as a basal insulin therapy given its once-weekly dosing schedule. With ultra long-acting insulin, AntriaBio is targeting a $10 billion global market. Once daily insulin products, comprised of Sanofi's Lantus

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details